Literature DB >> 20220349

Current controversies in the cardiovascular screening of athletes.

Jonathan Drezner1, Stuart Berger, Robert Campbell.   

Abstract

The sudden death of a young athlete on the playing field remains the most devastating medical event in sports, with compelling reasons to implement effective preventive strategies. Preparticipation screening is widely practiced, but universal agreement regarding the most appropriate method for cardiovascular screening is lacking. The addition of a resting 12-lead electrocardiogram (ECG) to a comprehensive personal and family history and physical examination will increase detection of those athletes with potentially lethal cardiovascular disorders at risk for sudden cardiac death. However, complex issues regarding feasibility, false positive results, cost-effectiveness, and physician and health system infrastructure still remain regarding large-scale implementation of ECG screening in the United States. When used, ECG interpretations based on modern criteria to distinguish abnormal findings from physiologic alterations in athletes must be applied to ensure acceptable accuracy.

Entities:  

Mesh:

Year:  2010        PMID: 20220349     DOI: 10.1249/JSR.0b013e3181d573d6

Source DB:  PubMed          Journal:  Curr Sports Med Rep        ISSN: 1537-890X            Impact factor:   1.733


  2 in total

1.  Standardised pre-competitive screening of athletes in some European and African countries: the SMILE study.

Authors:  Deodato Assanelli; Assanelli Deodato; Andrea Ermolao; Ermolao Andrea; François Carre; Carré François; Asterios Deligiannis; Deligiannis Asterios; Klaus Mellwig; Klaus Mellwig; Mellwig Klaus; Mohamed Tahmi; Tahmi Mohamed; Bruno Mario Cesana; Cesana Bruno Mario; Rosella Levaggi; Levaggi Rosella; Paola Aliverti; Aliverti Paola; Sanjay Sharma; Sharma Sanjay
Journal:  Intern Emerg Med       Date:  2013-05-26       Impact factor: 3.397

2.  Author's reply to pgs. 117-9, 120-2.

Authors:  Farzin Halabchi
Journal:  Asian J Sports Med       Date:  2011-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.